Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease

被引:0
|
作者
Jiang, Hao [1 ,2 ]
Yu, Hongsheng [1 ,2 ]
Hu, Can [1 ,2 ]
Huang, Yinan [1 ,2 ]
Yang, Bilan [3 ]
Xi, Xiaoli [1 ,2 ]
Lei, Yiming [1 ,2 ]
Wu, Bin [1 ,2 ]
Yang, Yidong [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Gastroenterol, 600 Tianhe Rd, Guangzhou 510630, Peoples R China
[2] Guangdong Prov Key Lab Liver Dis Res, Guangzhou, Guangdong, Peoples R China
[3] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou 510230, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
Chronic hepatitis b; Compensated advanced chronic liver disease; Fibroscan; Liver-related events; Prognosis; Trajectory; PROGRESSION; ELASTOGRAPHY; FIBROSIS; BIOPSY; RISK;
D O I
10.1016/j.aohep.2025.101788
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction and Objectives: Liver stiffness measurements (LSMs) offer a noninvasive method for monitoring liver disease development. This study evaluated the prognostic value of different LSM trajectories in chronic hepatitis B (CHB) and compensated advanced chronic liver disease (cACLD) patients. Materials and Methods: We retrospectively analyzed 1272 CHB and cACLD patients with at least two LSMs, applied group-based trajectory modeling (GBTM) to identify distinct LSM trajectories, and used a Cox model to analyze their associations with liver-related events (LREs) and mortality risk. Results: Patients were categorized into five groups with distinct LSM trajectories: 67 (8.5 %), 13 (11 %), 36 (23.5 %), 34(27.6 %) and 23 (25.0 %) developed LREs in Groups 1-5. The low stable trajectory (Group 3), the medium gradual decrease trajectory (Group 4) and high quickly decrease followed by increase trajectory (Group 5) had higher LREs risks than the low gradual decrease trajectory (Group 1) (adjusted HRs 2.26, 2.39, 2.67; 95 % CIs 1.50-3.40, 1.57-3.66, 1.61-4.43, respectively). Similar elevated risks were observed for hepatic decompensation, hepatocellular carcinoma (HCC), liver-related and all-cause mortality, except that there was no significant difference in the risk of HCC between Groups 4 and 1 (aHR 0.66, 0.36-1.23). When comparing Group 1 with the medium quickly decrease trajectory (Group 2), no significant differences were noted in the prognosis (P > 0.05). Notably, age over 40, high LSM, low PLT, and high total bilirubin were linked to high-risk trajectories (Groups 3-5). Conclusions: Monitoring LSM trajectories improves prognostic prediction in CHB and cACLD compared with single measurements and may guide personalized treatment strategies. (c) 2025 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页数:9
相关论文
共 50 条
  • [31] HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease
    Semmler, Georg
    Meyer, Elias Laurin
    Kozbial, Karin
    Schwabl, Philipp
    Hametner-Schreil, Stefanie
    Zanetto, Alberto
    Bauer, David
    Chromy, David
    Simbrunner, Benedikt
    Scheiner, Bernhard
    Stattermayer, Albert F.
    Pinter, Matthias
    Schofl, Rainer
    Russo, Francesco Paolo
    Greenfield, Helena
    Schwarz, Michael
    Schwarz, Caroline
    Gschwantler, Michael
    Lopez, Sonia Alonso
    Luisa Manzano, Maria
    Ahumada, Adriana
    Banares, Rafael
    Pons, Monica
    Rodriguez-Tajes, Sergio
    Genesca, Joan
    Lens, Sabela
    Trauner, Michael
    Ferenci, Peter
    Reiberger, Thomas
    Mandorfer, Mattias
    JOURNAL OF HEPATOLOGY, 2022, 76 (04) : 812 - 821
  • [32] How Can We Enhance the Performance of Liver Stiffness Measurement Using FibroScan in Diagnosing Liver Cirrhosis in Patients With Chronic Hepatitis B?
    Kim, Seung Up
    Kim, Do Young
    Park, Jun Yong
    Lee, Fin Ha
    Ahn, Sang Hoon
    Kim, Ja Kyung
    Paik, Yong Han
    Lee, Kwan Sik
    Chon, Chae Yoon
    Choi, Eun Hee
    Song, Ki Jun
    Park, Young Ayun
    Han, Kwang-Hyub
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2010, 44 (01) : 66 - 71
  • [33] Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B
    Wong, G. L. -H.
    Chan, H. L. -Y.
    Choi, P. C. -L.
    Chan, A. W. -H.
    Yu, Z.
    Lai, J. W. -Y.
    Chan, H. -Y.
    Wong, V. W. -S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (02) : 197 - 208
  • [34] The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis
    Shen, Yue
    Wu, Sheng-Di
    Wu, Ling
    Wang, Si-Qi
    Chen, Yao
    Liu, Li-Li
    Li, Jing
    Yang, Chang-Qing
    Wang, Ji-Yao
    Jiang, Wei
    HEPATOLOGY INTERNATIONAL, 2019, 13 (05) : 560 - 572
  • [35] Liver stiffness measurement reliability and main determinants of point shear-wave elastography in patients with chronic liver disease
    Fraquelli, M.
    Baccarin, A.
    Casazza, G.
    Conti, C. B.
    Giunta, M.
    Massironi, S.
    Invernizzi, F.
    Donato, M. F.
    Maggioni, M.
    Aghemo, A.
    Conte, D.
    Colombo, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (04) : 356 - 365
  • [36] aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients
    Fan, Rong
    Li, Guanlin
    Yu, Ning
    Chang, Xiujuan
    Arshad, Tamoore
    Liu, Wen-Yue
    Chen, Yan
    Wong, Grace Lai-Hung
    Jiang, Yiyue
    Liang, Xieer
    Chen, Yongpeng
    Jin, Xiao-Zhi
    Dong, Zheng
    Leung, Howard Ho-Wai
    Wang, Xiao-Dong
    Zeng, Zhen
    Yip, Terry Cheuk-Fung
    Xie, Qing
    Tan, Deming
    You, Shaoli
    Ji, Dong
    Zhao, Jun
    Sanyal, Arun J.
    Sun, Jian
    Zheng, Ming-Hu
    Wong, Vincent Wai-Sun
    Yang, Yongping
    Hou, Jinlin
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (12) : 3070 - +
  • [37] Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients
    Liu, Jie
    Ma, Ying
    Han, Ping
    Wang, Jing
    Liu, Yong-gang
    Shi, Rui- fang
    Li, Jia
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2022, 46 (08)
  • [38] Is lamivudine a safe and effective therapy for patients with chronic hepatitis B and advanced liver disease?
    Karayiannis, P
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2005, 2 (03): : 138 - 139
  • [39] Dynamic Changes in Liver Stiffness in Patients with Chronic Hepatitis B Undergoing Antiviral Therapy
    Lazar, Alin
    Sporea, Ioan
    Popa, Alexandru
    Lupusoru, Raluca
    Gherhardt, Diana
    Mare, Ruxandra
    Apostu, Alexandru
    Hnatiuc, Madalina
    Sirli, Roxana
    DIAGNOSTICS, 2022, 12 (11)
  • [40] Advanced liver disease in Russian children and adolescents with chronic hepatitis C
    Turkova, Anna
    Volynets, Galina V.
    Crichton, Siobhan
    Skvortsova, Tamara A.
    Panfilova, Victoria N.
    Rogozina, Natalia V.
    Khavkin, Anatoly I.
    Tumanova, Elena L.
    Indolfi, Giuseppe
    Thorne, Claire
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (07) : 881 - 892